QL2109
- Generic Name
- QL2109
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Phase 3
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT06742138
A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT06371534
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath